juice-email-cli 2.4.13 → 2.4.14

This diff represents the content of publicly available package versions that have been released to one of the supported registries. The information contained in this diff is provided for informational purposes only and reflects changes between package versions as they appear in their respective public registries.
Files changed (5) hide show
  1. package/edm/elabscience/series/literature/default/juice.yaml +3 -2
  2. package/edm/elabscience/series/literature/default/snippet.html +3 -1
  3. package/edm/procell/series/literature/default/juice.yaml +3 -2
  4. package/edm/procell/series/literature/default/snippet.html +3 -1
  5. package/package.json +1 -1
package/edm/elabscience/series/literature/default/juice.yaml CHANGED
@@ -11,7 +11,7 @@
11
11
  # ─── 模板变量（Mustache 语法）────────────────────────────────────────────────
12
12
  variables:
13
13
  overview:
14
- image: https://elabcomfile.oss-us-west-1.aliyuncs.com/edm/202605211020/Nature Medicine.webp
14
+ image: https://elabcomfile.oss-us-west-1.aliyuncs.com/edm/202605211020/overview.webp
15
15
  title: "Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial"
16
16
  link: https://www.nature.com/articles/s41591-026-04366-x
17
17
  publicationDate: April 29 2026
@@ -21,7 +21,8 @@ variables:
21
21
  keywords: Immune Thrombocytopenia (ITP), Nicotinamide Mononucleotide (NMN), CD38-NAD<sup>+</sup> Axis
22
22
 
23
23
  information:
24
- image: https://elabcomfile.oss-us-west-1.aliyuncs.com/edm/202605211020/CD38-NAD.webp
24
+ image:
25
+ - https://elabcomfile.oss-us-west-1.aliyuncs.com/edm/202605211020/information.webp
25
26
  content: "This study identifies the CD38-NAD<sup>+</sup> axis as an immunometabolic checkpoint in ITP. Anti-CD38 antibodies deplete NAD<sup>+</sup>, driving M1 macrophages and FcγRI upregulation, which increases platelet phagocytosis. Restoring NAD<sup>+</sup> via CD38 inhibition or NMN reprograms macrophages to a resting state and blocks platelet destruction without affecting humoral immunity. In 25 refractory ITP patients, low-dose NMN (450 mg bid × 2 weeks) was well tolerated: 20% achieved platelets ≥50×10<sup>9</sup>/L, and 52% maintained response at week 8, with stable immunoglobulin levels. Thus, targeting CD38-NAD<sup>+</sup> metabolism offers a non-antibody-depleting therapeutic strategy."
26
27
  link: https://www.procellsystem.com/resources/publications
27
28
  buttonText: View More Publications
package/edm/elabscience/series/literature/default/snippet.html CHANGED
@@ -63,7 +63,9 @@
63
63
 
64
64
  <tr>
65
65
  <td rowspan="2" style="padding-right: 12px;" class="image-box align-middle">
66
- <img src="{{information.image}}" />
66
+ {{#information.image}}
67
+ <img src="{{.}}" />
68
+ {{/information.image}}
67
69
  </td>
68
70
  <td class="h-0 {{#information.link}}pb-24{{/information.link}}">
69
71
  <p>{{information.content}}</p>
package/edm/procell/series/literature/default/juice.yaml CHANGED
@@ -11,7 +11,7 @@
11
11
  # ─── 模板变量（Mustache 语法）────────────────────────────────────────────────
12
12
  variables:
13
13
  overview:
14
- image: https://pri-cella.oss-ap-southeast-1.aliyuncs.com/edm/202604211419/Ischemic stroke.webp
14
+ image: https://pri-cella.oss-ap-southeast-1.aliyuncs.com/edm/202604211419/overview.webp
15
15
  title: "Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial"
16
16
  link: https://www.nature.com/articles/s41467-026-70340-3
17
17
  publicationDate: April 29 2026
@@ -21,7 +21,8 @@ variables:
21
21
  keywords: Immune Thrombocytopenia (ITP), Nicotinamide Mononucleotide (NMN), CD38-NAD<sup>+</sup> Axis
22
22
 
23
23
  information:
24
- image: https://pri-cella.oss-ap-southeast-1.aliyuncs.com/edm/202604211419/View More Publications.webp
24
+ image:
25
+ - https://pri-cella.oss-ap-southeast-1.aliyuncs.com/edm/202604211419/information.webp
25
26
  content: "This study identifies the CD38-NAD<sup>+</sup> axis as an immunometabolic checkpoint in ITP. Anti-CD38 antibodies deplete NAD<sup>+</sup>, driving M1 macrophages and FcγRI upregulation, which increases platelet phagocytosis. Restoring NAD<sup>+</sup> via CD38 inhibition or NMN reprograms macrophages to a resting state and blocks platelet destruction without affecting humoral immunity. In 25 refractory ITP patients, low-dose NMN (450 mg bid × 2 weeks) was well tolerated: 20% achieved platelets ≥50×10<sup>9</sup>/L, and 52% maintained response at week 8, with stable immunoglobulin levels. Thus, targeting CD38-NAD<sup>+</sup> metabolism offers a non-antibody-depleting therapeutic strategy."
26
27
  link: https://www.procellsystem.com/resources/publications
27
28
  buttonText: View More Publications
package/edm/procell/series/literature/default/snippet.html CHANGED
@@ -63,7 +63,9 @@
63
63
 
64
64
  <tr>
65
65
  <td rowspan="2" style="padding-right: 12px;" class="image-box align-middle">
66
- <img src="{{information.image}}" />
66
+ {{#information.image}}
67
+ <img src="{{.}}" />
68
+ {{/information.image}}
67
69
  </td>
68
70
  <td class="h-0 {{#information.link}}pb-24{{/information.link}}">
69
71
  <p>{{information.content}}</p>
package/package.json CHANGED
@@ -1,6 +1,6 @@
1
1
  {
2
2
  "name": "juice-email-cli",
3
- "version": "2.4.13",
3
+ "version": "2.4.14",
4
4
  "type": "module",
5
5
  "description": "CLI tool to generate email-client-compatible HTML with juice (CSS inlining) + Mustache templating + minification",
6
6
  "main": "src/index.js",